FSD Pharma is bringing innovative neuro disorders therapies to millions of patients in need.
MISSION STATEMENT
To develop novel solutions for brain and inflammatory disorders
VISION
To be a world class innovation driven biopharmaceutical company to improve the quality of life of patients
VALUES
Commitment, hard work and integrity
A Revolutionary Rapid Alcohol Detoxification Drink
Created by Scientists & Expert Clinical Research Team at FSD Pharma
Led by Former Executives from Coca-Cola and Celsius Holdings
UNBUZZD™ is led by a very experienced and successful beverage team
John Duffy spent over 22 years in the Coca-Cola (NYSE: KO) system including roles of increasing responsibilities across multiple functions. In his last role at Coca-Cola as Vice President of National Sales, John led the customer management team responsible for the Coca-Cola systems’ largest foodservice distributor, Sysco.
Gerry David is best known for his five-year tenure as Chief Executive Officer at zero-calorie fitness drink maker Celsius Holdings, Inc. (NASDAQ: CELH) where he spearheaded a turnaround that resulted in a global sales explosion, influx of capital from notable strategic investors, and a rise in market capitalization that increased shareholder value 35-fold by exceeding $9 billion.
Kevin Harrington is the inventor of the infomercial, Shark on Shark Tank, Fortune 100 investor, philanthropist, and author. Kevin has launched over 1,000 products in over 100 countries in dozens of languages, creating over $6 billion in global sales, and was instrumental in the creation of Celsius’ influencer marketing program.
Year 2023 marks the first true convergence of science and accelerating alcohol metabolism. Until now, when one consumes excess alcohol, “time” has been the only answer to return to sobriety, creating a great need for a solution that provides faster and more effective recovery. In 2023, we are bringing out the science to find clarity. This is not just another hangover remedy!
We’re talking about UNBUZZD™, a new, great tasting functional beverage being developed by FSD Pharma with the expectations of providing relief from inebriation and accelerating alcohol metabolism leading to reduced Breath Alcohol Concentration (BrAC). No more hyperbole. Just Science.
Patented new chemical entity (NCE)
Lucid-MS is a patented neuroprotective compound that has demonstrated in preclinical models to prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions. Lucid-MS has shown excellent results in several animal models, as demonstrated in the video below.
Excellent efficacy in various preclinical animal models
Accelerates functional recovery of mouse models of Multiple Sclerosis, preserves myelin, and reduces zonal degradation
Does not suppress immune system (non-immunomodulatory)
Potential oral administration with easy dosing regimen
FSD Pharma has completed the dosing of healthy human volunteers for phase-1 clinical trials for Lucid-MS.
Today there is no cure for Multiple Sclerosis.
FSD Pharma (“HUGE”) is trying to change this for millions of people.
*Data current as of May 14, 2024
A balance sheet represented by no debt and enough working capital to carry operations of 2025
Developing novel myelin repairing compounds for the treatment of neurodegenerative and neuropsychiatric diseases
Two lead candidates to improve patient outcomes and address large populations ($23B multiple sclerosis market and $238B mental health market)
Phase-1 dosing of all patients completed for Lucid-MS (Lucid-21-302) for first in-human safety and tolerability investigation. This trial will be First In Class for its Multiple Sclerosis drug candidate
World class and experienced team of scientists, researchers and doctors from world class institutions or organizations
Please send investor relations inquiries to the following email: